Frequency & factors associated with apparent resistant hypertension among Ghanaians in a multicenter study.
Ghanaians
apparent
hypertension
prevalence
resistant
Journal
Journal of clinical hypertension (Greenwich, Conn.)
ISSN: 1751-7176
Titre abrégé: J Clin Hypertens (Greenwich)
Pays: United States
ID NLM: 100888554
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
06
04
2020
revised:
23
05
2020
accepted:
31
05
2020
pubmed:
21
8
2020
medline:
27
5
2021
entrez:
21
8
2020
Statut:
ppublish
Résumé
Apparent resistant hypertension (ARH) is rife among people living with hypertension and is associated with significant morbidity and mortality. There is however paucity of data from sub-Saharan Africa on the burden of ARH. We sought to report on the frequency and factors associated with ARH among a cohort of Ghanaians with hypertension. A cross-sectional study involving 2912 participants with hypertension enrolled at five health facilities in Ghana. ARH was defined as either office BP ≥ 140/90 mm Hg on 3 or more antihypertensive medications or on 4 or more antihypertensive medications regardless of BP. Factors associated with ARH were evaluated in a multivariate logistic regression model. We found 550 out of 2,912 (18.9%) of study participants had ARH. Out of these 550 subjects, 511 (92.9%) were on 3 or more antihypertensive medications with BP ≥ 140/90 mm Hg and 39 (7.1%) were on 4 or more antihypertensive medications with BP ≥ 140/90 mm Hg. The prevalence of ARH was 15.5% among elderly aged 75 + years (n = 341), 20.7% among 65-74 years (n = 588), and 18.9% among those ≤ 64 years (n = 1983). The adjusted odds ratio (95% CI) of factors independently associated with ARH was duration of hypertension, 1.05 (1.03-1.06) for each year rise; eGFR < 60 mL/min, 1.73 (1.33-2.25); and diabetes mellitus, 0.59 (0.46-0.76). Attaining secondary level education and residence in a peri-urban setting were significantly associated with ARH though not in a dose-dependent manner. ARH is rife among Ghanaians and may negatively impact on cardiovascular outcomes in the long term.
Identifiants
pubmed: 32815641
doi: 10.1111/jch.13974
pmc: PMC8029809
doi:
Substances chimiques
Antihypertensive Agents
0
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1594-1602Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL152188
Pays : United States
Organisme : NINDS NIH HHS
ID : R21 NS094033
Pays : United States
Organisme : Bill & Melinda Gates Foundation
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01HL152188
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Hypertension. 2016 Oct;68(4):995-1003
pubmed: 27528066
Lancet Glob Health. 2018 Apr;6(4):e436-e446
pubmed: 29496511
BMJ Open. 2012 Aug 24;2(4):
pubmed: 22923629
Prog Cardiovasc Nurs. 2000 Summer;15(3):90-6
pubmed: 10951950
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
JAMA. 2013 Sep 4;310(9):959-68
pubmed: 24002282
Cardiovasc Diabetol. 2012 Apr 10;11:32
pubmed: 22490507
J Hum Hypertens. 2014 Aug;28(8):463-8
pubmed: 24430707
J Hypertens. 2015 Feb;33(2):195-211
pubmed: 25485720
Hypertension. 2013 Oct;62(4):691-7
pubmed: 23918752
Hypertens Res. 2012 Feb;35(2):148-52
pubmed: 22129517
Hypertension. 2015 Feb;65(2):291-8
pubmed: 25385758
J Neurol Sci. 2019 Jan 15;396:140-147
pubmed: 30471633
Hypertension. 2004 Jan;43(1):10-7
pubmed: 14638619
Circulation. 2008 Jun 24;117(25):e510-26
pubmed: 18574054
Clin J Am Soc Nephrol. 2013 Sep;8(9):1583-90
pubmed: 23868902
Int J Obes Relat Metab Disord. 2002 Jan;26(1):48-57
pubmed: 11791146
Neuroepidemiology. 2010;35(1):36-44
pubmed: 20389123
Bull World Health Organ. 2014 Jan 1;92(1):10-19C
pubmed: 24391296
Pan Afr Med J. 2013 Oct 05;16:38
pubmed: 24570798
BMC Cardiovasc Disord. 2013 Aug 02;13:54
pubmed: 23915151
Curr Hypertens Rep. 2020 Jan 8;22(1):3
pubmed: 31916065
J Am Soc Hypertens. 2013 Nov-Dec;7(6):509-11
pubmed: 24035315
Lancet. 2016 Aug 20;388(10046):761-75
pubmed: 27431356
JAMA. 2003 May 28;289(20):2673-84
pubmed: 12771114
Lancet. 2012 Aug 11;380(9841):611-9
pubmed: 22883510
J Neurol Sci. 2015 Oct 15;357(1-2):240-5
pubmed: 26293417
Curr Opin Cardiol. 2005 Jul;20(4):296-300
pubmed: 15956826
BMJ Open. 2016 Sep 20;6(9):e011452
pubmed: 27650760
Blood Press. 2015;24(6):325-32
pubmed: 26364650
J Hypertens. 2016 Sep;34(9):1678-88
pubmed: 27488547
J Hypertens. 2010 Jul;28(7):1356-65
pubmed: 20375907
Circulation. 2011 Aug 30;124(9):1046-58
pubmed: 21824920
J Clin Hypertens (Greenwich). 2011 Jul;13(7):523-8
pubmed: 21762366
J Clin Hypertens (Greenwich). 2020 Sep;22(9):1594-1602
pubmed: 32815641
Hypertension. 2011 May;57(5):898-902
pubmed: 21444835
Gates Open Res. 2018 Feb 7;2:6
pubmed: 29757315
PLoS One. 2018 Mar 19;13(3):e0193494
pubmed: 29554106
J Clin Hypertens (Greenwich). 2019 Oct;21(10):1542-1550
pubmed: 31465141
Heart. 2019 Jan;105(2):98-105
pubmed: 30087099
Nat Rev Nephrol. 2013 Jan;9(1):51-8
pubmed: 23165303
Lancet. 2009 Mar 28;373(9669):1083-96
pubmed: 19299006
J Clin Hypertens (Greenwich). 2012 Oct;14(10):694-700
pubmed: 23031147